Evidence map›Paper›PMID 27802879›Full record

ArticleJournal of autoimmunity2017

An insulin-IAPP hybrid peptide is an endogenous antigen for CD4 T cells in the non-obese diabetic mouse.

Timothy A Wiles, Thomas Delong, Rocky L Baker, Brenda Bradley, Gene Barbour, Roger L Powell, Nichole Reisdorph, Kathryn Haskins

Abstract read
In one paragraph

Article in Journal of autoimmunity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. CD4Immunity · 2024
    Article
  12. Article
  13. Review
  14. The immunology of type 1 diabetes.Nature reviews. Immunology · 2024
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Timothy A WilesDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Denver, Anschutz Medical Campus, Aurora, CO 80045, USA.
Thomas DelongDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Denver, Anschutz Medical Campus, Aurora, CO 80045, USA.
Rocky L BakerDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Denver, Anschutz Medical Campus, Aurora, CO 80045, USA.
Brenda BradleyDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Denver, Anschutz Medical Campus, Aurora, CO 80045, USA.
Gene BarbourDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Denver, Anschutz Medical Campus, Aurora, CO 80045, USA.
Roger L PowellPharmaceutical Science, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Nichole ReisdorphPharmaceutical Science, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Kathryn HaskinsDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Denver, Anschutz Medical Campus, Aurora, CO 80045, USA. Electronic address: katie.haskins@ucdenver.edu.

Funding

Hybrid Peptides as Autoantigens for Diabetogenic CD4 T CellsR01DK081166 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI HASKINS, KATHRYN M, JAMES, EDDIE A · 2011 to 2024
$7.3M
NIDDK NIH HHS R01 DK081166
6 · The paper itself

Abstract

BDC-6.9, a diabetogenic CD4 T cell clone isolated from a non-obese diabetic (NOD) mouse, responds to pancreatic islet cells from NOD but not BALB/c mice. We recently reported that a hybrid insulin peptide (HIP), 6.9HIP, formed by linkage of an insulin C-peptide fragment and a fragment of islet amyloid polypeptide (IAPP), is the antigen for BDC-6.9. We report here that the core 12-mer peptide from 6.9HIP, centered on the hybrid peptide junction, is also highly antigenic for BDC-6.9. In agreement with the observation that BALB/c islet cells fail to stimulate the T cell clone, a single amino acid difference in the BALB/c IAPP sequence renders the BALB/c version of the HIP only weakly antigenic. Mutant peptide analysis indicates that each parent molecule-insulin C-peptide and IAPP-donates residues critical for antigenicity. Through mass spectrometric analysis, we determine the distribution of naturally occurring 6.9HIP across chromatographic fractions of proteins from pancreatic beta cells. This distribution closely matches the profile of the T cell response to the fractions, confirming that 6.9HIP is the endogenous islet antigen for the clone. Using a new MHC II tetramer reagent, 6.9HIP-tet, we show that T cells specific for the 6.9HIP peptide are prevalent in the pancreas of diabetic NOD mice. Further study of HIPs and HIP-reactive T cells could yield valuable insight into key factors driving progression to diabetes and thereby inform efforts to prevent or reverse this disease.

Indexed as

Amino Acid SequenceAnimalsAutoantigensCD4-Positive T-LymphocytesCells, CulturedC-PeptideEpitopes, T-LymphocyteInsulinIslet Amyloid PolypeptideLymphocyte ActivationMiceMice, Inbred BALB CMice, Inbred NODMice, KnockoutAutoantigensC-PeptideEpitopes, T-LymphocyteInsulinIslet Amyloid PolypeptideAutoimmune type 1 diabetesHybrid insulin peptides (HIPs)Non-obese diabetic (NOD) mousePeptide fusionTetramer

Identifiers

PMID27802879
PMCPMC5337175

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.